Topic

All

12
Apr
2023

The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen

Today’s guest on The Long Run is Catherine Stehman-Breen. Catherine is the CEO of Boston-based Chroma Medicine. Chroma is working on therapies that control gene expression through epigenetic editing. People have heard a lot about editing of the genome with CRISPR, and then subsequent refinements of the technology known as base editing and prime editing. The question at Chroma is...
Read More
10
Apr
2023

In Support of FDA’s Authority to Regulate Medicines

On Friday, April 7, a federal judge with no scientific training fundamentally undermined the bipartisan authority granted by Congress to the Food and Drug Administration to approve and regulate safe, effective medicines for every American. District Judge Matthew Kacsmaryk issued a decision that overturns the FDA’s 23-year-old approval of mifepristone, the primary medicine used in abortion and miscarriage care, and...
Read More
8
Apr
2023

Tech, Pharma, and the Uneven Distribution of the AI-Enabled Future

The worlds of technology and entrepreneurship are captivated by recent advances in generative AI and large language models (LLMs).  The arrival of ChatGPT, developed by OpenAI (a startup partnered with Microsoft), caused Google to declare a “Code Red,” akin to “pulling the fire alarm,” the New York Times explained. The latest class of startups at Y Combinator are reportedly flocking...
Read More
2
Apr
2023

New Book Contemplates How Generative AI Will Serve Man

In 1935, Astounding Science — the premier science fiction magazine of the day, and perhaps ever — published “Proxima Centauri.” It was a short story envisioning an encounter between a voyaging earth spacecraft and a ship from a nearby star system. Written by Murray Leinster (William Fitzgerald Jenkins), the tale features the original use of the phrase “first contact” in...
Read More
29
Mar
2023

Timmerman Traverse for Life Science Cares is Back

The next biotech team adventure is here. I’m thrilled to announce the Timmerman Traverse for Life Science Cares 2023. We’re on a mission to raise $1 million. We’re giving it all back to the most vulnerable people in the communities where we live and work. This trip involves shared sacrifice. We will cover 20+ miles and gain 8,000 feet of...
Read More
23
Mar
2023

Welcome to the AI Irruption

Biopharma, like the rest of the world, appears to be on the threshold of profound, technology-induced change. Incredible advances in artificial intelligence, manifested most recently in GPT-4, are here.  This technology, Ezra Klein explains in the New York Times, “changes everything.”  Bill Gates describes it as “the most important advance in technology since the graphical user interface,” and declares, “the...
Read More
16
Mar
2023

The Last Mile of Hepatitis C Treatment

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
14
Mar
2023

The Future of Neuroscience Drug R&D: Ryan Watts on The Long Run

Today’s guest on The Long Run is Ryan Watts. Ryan is the co-founder and CEO of South San Francisco-based Denali Therapeutics. Denali is one of the prominent development-stage biotech companies working on treatments for neurodegenerative diseases. It has a pipeline with seven drug candidates in clinical development. It’s developing small molecules and large molecules against a range of neurodegenerative diseases...
Read More